Navigation Links
Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results
Date:8/4/2011

ontraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. Serious anaphylactoid reactions, including death in a patient with asthma, have been reported in patients administered acetylcysteine intravenously. Acetadote should be used with caution in patients with asthma or where there is a history of bronchospasm. The total volume administered should be adjusted for patients weighing less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed. If volume is not adjusted fluid overload can occur, potentially resulting in hyponatremia, seizure and death.  For full prescribing information, visit www.acetadote.net.

About KristaloseKristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Initial dosing may produce flatulence and intestinal cramps, which are usually transient.  Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia and hypernatremia. Nausea and vomiting have been reported. Use with caution in diabetics. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing information, visit www.kristalose.com.

Forward-Looking StatementsThis press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
5. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
6. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
7. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
8. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
9. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
10. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
11. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced ... older adults suffering from the severe cold weather that has ... committed to helping those in need; so to support these ... contributions up to $250,000, which could mean up to $500,000 ...
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
...  BioDelivery Sciences International, Inc. (Nasdaq: BDSI ... license and development agreement with Endo Pharmaceuticals (Nasdaq: ... to develop and commercialize BEMA Buprenorphine for the ... patented and proven BioErodible MucoAdhesive (BEMA) technology to ...
... conjunction with its fourth quarter 2011 earnings release (expected to ... Inc. (NYSE: CVD ) is pleased to invite ... will be broadcast live over the Internet on Thursday, January ... , What:       , , , Covance Fourth Quarter 2011 Earnings ...
Cached Medicine Technology:BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine 2BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine 3BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine 4BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine 5
(Date:4/23/2014)... of Alzheimer,s disease has been a rapidly evolving ... the latest crook in the research road, scientists ... between proteins associated with the disease. The report, ... Neuroscience , could have important implications for developing ... and colleagues explain that for years, research has ...
(Date:4/22/2014)... Jersey Institute of Technology (NJIT) today to join ... of the New Jersey Innovation Institute (NJII), an ... business innovation through the leveraging of industry, government, ... Cory Booker, Panasonic Corp. of North America Chairman ... Kim Guadagno, New Jersey Secretary of Higher Education ...
(Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
(Date:4/22/2014)... Researchers at UT Southwestern Medical Center are making breakthroughs ... , A team of physician-scientists at UT Southwestern ... hormone with natural anti-depressant properties) works inside the brain. ... for depression in the form of a neuroprotective drug ... online in April,s issue of Molecular Psychiatry, ...
(Date:4/22/2014)... (SACRAMENTO, Calif.) The risk of pregnancy among women ... sterilization is more than 10 times greater over a ... sterilization, a study by researchers at Yale University and ... in the medical journal Contraception , the study ... sterilization method marketed under the brand name Essure. ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... pain today are much less likely to die, or to experience ... according to a new international study. ,It's the first ... rate of heart failure and death over such a short time ... change occurred at the same time that hospitals increased their use ...
... failed to improve symptoms of moderate to severe chronic ... multi-center trial. ,The results of the ... the first issue of the May American Journal of ... Thoracic Society. ,According to an editorial commenting ...
... Junior doctors who do not get training posts through ... further misery because the government is stalling on ... warns. ,Latest figures show that 34,250 doctors ... The government has so far given no commitment that ...
... cream for enhancing sexual desire in female cancer survivors did ... Mayo clinic has shown. ,A low sex ... to a previous study which pointed a link between androgen ... levels, this new study was conducted on 150 post menopausal ...
... is now infusing roasted sunflower seeds with caffeine ... provide players and other people the extra energy needed to ... been under development since an year, are grown in North ... Products) plant at Willow Lake where caffeine, taurine, lysine and ...
... there is no hard and fast rule as to how a ... more than glad to endorse that view as standard positions ... motherly feelings to override. , Take the case of ... when her daughter Deborah was born. ,As manager of ...
Cached Medicine News:Health News:Good News for Sufferers of Heart Attack, Chest Pain 2Health News:Good News for Sufferers of Heart Attack, Chest Pain 3Health News:Good News for Sufferers of Heart Attack, Chest Pain 4Health News:Anti-inflammatory Drug Fails to Improve COPD Symptoms 2Health News:Junior Doctors Facing More Misery Because of Contract Deadlock: BMA 2Health News:Caffeinated Sunflower Seeds To Hit The Market 2Health News:New Research Promises To Take The Pain Off Breast Feeding 2Health News:New Research Promises To Take The Pain Off Breast Feeding 3
First to USA-market, this revolutionary technology combines CBC and CRP analysis for stat results of 17 parameters within 4.5 minutes!...
StarClose Clip Applier, (includes), Clip Applier, 6F Exchange Sheath, 6F Dilator, 0.038 50 cm J-Tip Guide Wire ...
... 5.5x magnification., ,Higher magnification for advanced ... true image. Edge to edge clarity ... for intricate surgical applications. The XL's ... anti-reflective coating to produce a superior ...
... and 3.0x magnification. The true benefit of ... while maintaining focal clarity is made possible ... The lightweight aluminum bar and individual pupillary ... and optimal focal alignment, eliminating headache and ...
Medicine Products: